Christopher Fenimore

Christopher Fenimore

Executive Vice President, Finance and Chief Financial Officer6atRegeneron Pharmaceuticals· In proxies 2024–2025

Pay in FY2024Regeneron Pharmaceuticals stock -18.9% the same year

Christopher Fenimore was paid $6.3M in FY2024 (Dec). Regeneron Pharmaceuticals stock fell 18.9% that year.

Pay$100 in the stock at the end of FY23 → $81
Pay is from the Summary Compensation Table of each Regeneron Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Regeneron PharmaceuticalsPublic company · 2 yr
    • Executive Vice President, Finance and Chief Financial Officer62024 – Present · 2 yrStock in role -4%

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?